{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tsui TCO"],"funding":["Canadian Partnership Against Cancer Corporation and Health Canada","Sunnybrook Alternative Funding Plan Association","EuroQol Research Foundation"],"pagination":["645"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12651012"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["32(11)"],"pubmed_abstract":["<h4>Background</h4>EQ-5D-3L health utilities inform health technology assessments in oncology, often derived from clinical trials enrolling highly selected populations, which may over-estimate real-world health utilities. Little is known about the association between socioeconomic status (SES) and EQ-5D-3L health utilities. Our objective was to examine EQ-5D-3L health utilities across SES in a real-world sample of patients with cancer.<h4>Methods</h4>We conducted a cross-sectional analysis of EQ-5D-3L responses from 170 adult patients with cancer accrued from an Ontario oncology centre. We fitted multivariable linear regression models to estimate associations between covariates and EQ-5D-3L health utilities.<h4>Results</h4>Lower EQ-5D-3L health utilities were significantly associated with the lowest and undisclosed family income categories in models with and without birth sex (<i>p</i> < 0.05). In the model including birth sex, disutility estimates for lowest family income (<CAD 29K) and undisclosed income was -0.202, 95% CI (-0.371 to -0.033), and -0.123 (-0.235 to -0.012), respectively. For the model excluding birth sex, disutility estimates for lowest income and undisclosed income was -0.163 (-0.280 to -0.046) and -0.106 (-0.184 to -0.028).<h4>Conclusions</h4>Lower EQ-5D-3L health utilities were significantly associated with low income and nondisclosure, highlighting the need to incorporate SES in analyzing health utilities in cancer care."],"journal":["Current oncology (Toronto, Ont.)"],"pubmed_title":["Examining the Association Between Equity-Related Factors and EQ-5D-3L Health Utilities of Patients with Cancer."],"pmcid":["PMC12651012"],"funding_grant_id":["#1456-PD","#SHS-20-020","#13283"],"pubmed_authors":["Chan KKW","Mercer RE","Tsui TCO","Pullenayegum EM"],"additional_accession":[]},"is_claimable":false,"name":"Examining the Association Between Equity-Related Factors and EQ-5D-3L Health Utilities of Patients with Cancer.","description":"<h4>Background</h4>EQ-5D-3L health utilities inform health technology assessments in oncology, often derived from clinical trials enrolling highly selected populations, which may over-estimate real-world health utilities. Little is known about the association between socioeconomic status (SES) and EQ-5D-3L health utilities. Our objective was to examine EQ-5D-3L health utilities across SES in a real-world sample of patients with cancer.<h4>Methods</h4>We conducted a cross-sectional analysis of EQ-5D-3L responses from 170 adult patients with cancer accrued from an Ontario oncology centre. We fitted multivariable linear regression models to estimate associations between covariates and EQ-5D-3L health utilities.<h4>Results</h4>Lower EQ-5D-3L health utilities were significantly associated with the lowest and undisclosed family income categories in models with and without birth sex (<i>p</i> < 0.05). In the model including birth sex, disutility estimates for lowest family income (<CAD 29K) and undisclosed income was -0.202, 95% CI (-0.371 to -0.033), and -0.123 (-0.235 to -0.012), respectively. For the model excluding birth sex, disutility estimates for lowest income and undisclosed income was -0.163 (-0.280 to -0.046) and -0.106 (-0.184 to -0.028).<h4>Conclusions</h4>Lower EQ-5D-3L health utilities were significantly associated with low income and nondisclosure, highlighting the need to incorporate SES in analyzing health utilities in cancer care.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-05-20T03:18:26.559Z","creation":"2026-05-20T03:13:12.484Z"},"accession":"S-EPMC12651012","cross_references":{"pubmed":["41294707"],"doi":["10.3390/curroncol32110645"]}}